Purpose of reviewThis review will briefly revise the evidence concerning the pharmacological inhibition of Apolipoprotein CIII (ApoCIII) in patients with hypertriglyceridemia.Recent findingsApoCIII is a plasma apolipoprotein playing a major role in the metabolism of triglyceride-rich lipoproteins, namely chylomicrons and very-low-density lipoproteins as well as in the pathological processes involved in atherosclerosis. Therefore, ApoCIII is a potential new target for reducing plasma levels of TRLs and, thereby, cardiovascular risk. In recent years, there have been extensive preclinical and clinical pharmacological studies aimed at testing drugs directed against ApoCIII.In this review, firstly we will summarize the molecular function of ApoCIII in lipoprotein metabolism. Then, we will examine the lipid-lowering potential of the pharmacological inhibition of ApoCIII based on the results of clinical trial employing Volansesorsen, the first approved antisense therapeutic oligonucleotide against ApoCIII mRNA. The future perspectives for ApoCIII inhibition will be also revised.

Recent Apolipoprotein CIII trials / Tramontano, Daniele; Bini, Simone; D'Erasmo, Laura; Arca, Marcello. - In: CURRENT OPINION IN LIPIDOLOGY. - ISSN 0957-9672. - 33:6(2022), pp. 309-318. [10.1097/MOL.0000000000000849]

Recent Apolipoprotein CIII trials

Tramontano, Daniele;Bini, Simone;D'Erasmo, Laura;Arca, Marcello
2022

Abstract

Purpose of reviewThis review will briefly revise the evidence concerning the pharmacological inhibition of Apolipoprotein CIII (ApoCIII) in patients with hypertriglyceridemia.Recent findingsApoCIII is a plasma apolipoprotein playing a major role in the metabolism of triglyceride-rich lipoproteins, namely chylomicrons and very-low-density lipoproteins as well as in the pathological processes involved in atherosclerosis. Therefore, ApoCIII is a potential new target for reducing plasma levels of TRLs and, thereby, cardiovascular risk. In recent years, there have been extensive preclinical and clinical pharmacological studies aimed at testing drugs directed against ApoCIII.In this review, firstly we will summarize the molecular function of ApoCIII in lipoprotein metabolism. Then, we will examine the lipid-lowering potential of the pharmacological inhibition of ApoCIII based on the results of clinical trial employing Volansesorsen, the first approved antisense therapeutic oligonucleotide against ApoCIII mRNA. The future perspectives for ApoCIII inhibition will be also revised.
2022
APOCIII; hypertriglyceridaemia; olezarsen; triglyceride lowering therapy; volanesorsen
01 Pubblicazione su rivista::01g Articolo di rassegna (Review)
Recent Apolipoprotein CIII trials / Tramontano, Daniele; Bini, Simone; D'Erasmo, Laura; Arca, Marcello. - In: CURRENT OPINION IN LIPIDOLOGY. - ISSN 0957-9672. - 33:6(2022), pp. 309-318. [10.1097/MOL.0000000000000849]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1689076
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 5
social impact